BioVersys (SIX: BIOV)

Last close As at 20/03/2026

CHF28.30

0.80 (2.91%)

Market capitalisation

CHF161m

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focussed on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Latest Insights

View More

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Marc Gitzinger

    CEO & Founder

  • Hernan Levett

    CFO